drugset / Trial / NCT07166211
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
Timeline
- Start
- 2025-11-27
- Primary completion
- 2026-11-02
- Completion
- 2027-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM512 | Unknown | — | Subcutaneous |